Results 321 to 330 of about 9,559,132 (390)

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

open access: yesMolecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti   +3 more
wiley   +1 more source

The European Nucleotide Archive in 2025. [PDF]

open access: yesNucleic Acids Res
David Y   +27 more
europepmc   +1 more source

School funding pressures in England [PDF]

open access: yes, 2018
Andrews, Jon, Lawrence, Tom
core  

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Article processing charges and health research output in low-income countries: funding cuts, implications for health policy and system management. [PDF]

open access: yesFront Health Serv
Eneh SC   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy